AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|
10 C
New York
Wednesday, October 28, 2026

Tag: result

newsFORsourcecompanycontentinformation1releasesmarket

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

OASE+ and Elsevier Agree Next-Phase Read and Publish Agreement to Expand Open Access Publishing in Japan

A new three-year term removes the annual cap on open access publishing under the Read and Publish agreement and extends eligibility beyond universitiesTOKYO, Oct. 26,...

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase...

Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365

NEW YORK, Oct. 25, 2026 /PRNewswire/ -- Consumer365 has recognized TORRAS in its review of the best iPhone cases for 2026, highlighting the Ostand Q3...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development,...

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research,...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as...

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation...

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24,...

DENARIUS METALS FILES TORAL PROJECT TECHNICAL REPORT ON SEDAR+

TORONTO, Oct. 23, 2026 /PRNewswire/ -- Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or "the Company") announced today the filing of...

DENARIUS METALS FILES TORAL PROJECT TECHNICAL REPORT ON SEDAR+

TORONTO, Oct. 23, 2026 /CNW/ -- Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or "the Company") announced today the filing of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResult

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers